Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment

Blood Cells, Molecules, and Diseases

Volumn 51, Issue 3, 2013, Pages 142-145

  Danjou, F ^a   Origa, R ^b   Anni, F ^a   Saba, L ^b   Cossa, S ^c   Podda, G ^c   Galanello, R ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Osp Regionale per le Microcitemie   (Italy)

^c Struttura Complessa Radiologia Presidio Ospedaliero Businco   (Italy)

Author keywords

Beta thalassemia; Heart siderosis; Iron chelation; Liver iron concentration; Magnetic resonance

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT;

ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; HEART; HEART HEMOSIDEROSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER; LONGITUDINAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THALASSEMIA MAJOR; TISSUE LEVEL;

BETA-THALASSEMIA; HEART SIDEROSIS; IRON CHELATION; LIVER IRON CONCENTRATION; MAGNETIC RESONANCE;

ADULT; BETA-THALASSEMIA; CHELATION THERAPY; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; YOUNG ADULT;

EID: 84881024010     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.06.001     Document Type: Article

References (15)

1. Modell B., Khan M., Darlison M., et al. Improved survival of thalassaemia major in the UK and relation to t2*cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 2008, 10:42.
2. Pennell D.J. T2* magnetic resonance and myocardial iron in thalassemia. Ann. N. Y. Acad. Sci. 2005, 1054:373-378.
3. Anderson L.J., Holden S., Davis B., et al. Cardiovascular t2-star (t2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 2001, 22:2171-2179.
4. Noetzli L.J., Carson S.M., Nord A.S., Coates T.D., Wood J.C. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008, 112:2973-2978.
5. Wood J.C., Enriquez C., Ghugre N., et al. Mri r2 and r2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
6. Tanner M.A., He T., Westwood M.A., Firmin D.N., Pennell D.J. Multi-center validation of the transferability of the magnetic resonance t2* technique for the quantification of tissue iron. Haematologica 2006, 91:1388-1391.
7. Origa R., Satta S., Matta G., Galanello R. Glutathione s-transferase gene polymorphism and cardiac iron overload in thalassaemia major. Br. J. Haematol. 2008, 142:143-145.
8. Tanner M.A., Galanello R., Dessi C., et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J. Cardiovasc. Magn. Reson. 2006, 8:543-547.
9. Tanner M.A., Galanello R., Dessi C., et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007, 115:1876-1884.
10. Galanello R., Agus A., Campus S., et al. Combined iron chelation therapy. Ann. N. Y. Acad. Sci. 2010, 1202:79-86.
11. Evans P., Kayyali R., Hider R.C., Eccleston J., Porter J.B. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl. Res. 2010, 156:55-67.
12. Porter J.B. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev. 2009, 23(Suppl. 1):S3-S7.
13. Anderson L.J., Wonke B., Prescott E., et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002, 360:516-520.
14. Hershko C., Link G., Konijn A.M., Cabantchik Z.I. Objectives and mechanism of iron chelation therapy. Ann. N. Y. Acad. Sci. 2005, 1054:124-135.
15. Pennell D.J., Berdoukas V., Karagiorga M., et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006, 107:3738-3744.